United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: Important lessons to learn

Europace

Volumn 15, Issue 8, 2013, Pages 1158-1165

  Jarman, Julian W E ^a   Todd, Derick M ^b  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

Implantable cardioverter defibrillator; Sudden cardiac death; Ventricular fibrillation

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BRUGADA SYNDROME; CARDIOMYOPATHY; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CHILD; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; DEATH; FOLLOW UP; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; ISCHEMIC CARDIOMYOPATHY; LONG QT SYNDROME; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; REOPERATION; SCHOOL CHILD; SUDDEN CARDIAC DEATH; T WAVE; UNITED KINGDOM;

EID: 84880949197     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut016     Document Type: Article

References (28)

1. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA III, Freedman RA, Gettes LS et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 2008;5:e1-62
2. Goette A, Cantu F, van Erven L, Geelen P, Halimi F, Merino JL et al. Performance and survival of transvenous defibrillation leads: Need for a European data registry. Europace 2009;11:31-4
3. Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010;363: 36-44
4. Dabiri Abkenari L, Theuns DA, Valk SD, Van Belle Y, de Groot NM, Haitsma D et al. Clinical experience with a novel subcutaneous implantable defibrillator system in a single center. Clin Res Cardiol 2011;100:737-44
5. Jarman JW, Lascelles K, Wong T, Markides V, Clague JR, Till J. Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: Cause for caution. Eur Heart J 2012;33:1351-9
6. Aydin A, Hartel F, Schlüter M, Butter C, Köbe J, Seifert M et al. Shock efficacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death: Initial multicenter experience. Circ Arrhythm Electrophysiol 2012;5: 913-9
7. Köbe J, Reinke F, Meyer C, Shin DI, Martens E, Kääb S et al. Implantation and follow-Up of totally subcutaneous versus conventional implantable cardioverterdefibrillators: A multicenter case-control study. Heart Rhythm 2013;10(1):29-36
8. Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, Maass AH, de Groot JR, van Oostrom AJ et al. The entirely subcutaneous implantable cardioverterdefibrillator: Initial clinical experience in a large Dutch cohort. J Am Coll Cardiol 2012;60:1933-9
9. Burke M, Toff WD, Ludmer PL, Barr CS, Beshai JF, ONeill PG et al. Comparisons during multiple postures of resting ECG's (COMPARE) study. Heart Rhythm 2009; 6:S126 (abstr
10. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: Calendar year 2009 -A World Society of Arrhythmia's project. Pacing Clin Electrophysiol 2011;34:1013-27
11. Pedersen SS, Lambiase P, Boersma LV, Murgatroyd F, Johansen JB, Reeve H et al. Evaluation of factors impacting clinical outcome and cost effectiveness of the S-ICD: Design and rationale of the EFFORTLESS S-ICD registry. Pacing Clin Electrophysiol 2012;35:574-9
12. Van Rees JB, Borleffs CJ, de Bie MK, Stijnen T, van Erven L, Bax JJ et al. Inappropriate implantable cardioverter-defibrillator shocks: Incidence, predictors, and impact on mortality. J Am Coll Cardiol 2011;57:556-62
13. Gilliam FR, Hayes DL, Boehmer JP, Day J, Heidenreich PA, Seth M et al. Real world evaluation of dual-zone ICD and CRT-D programming compared to single-zone programming: The Altitude Reduces study. J Cardiovasc Electrophysiol 2011;22: 1023-9
14. Botsch MP, Franzbach B, Opgen-Rhein B, Berger F, Will JC. ICD therapy in children and young adults: Low incidence of inappropriate shock delivery. Pacing Clin Electrophysiol 2010;33:734-41
15. Berul CI, Van Hare GF, Kertesz NJ, Dubin AM, Cecchin F, Collins KK et al. Results of a multicentre retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol 2008;51:1685-91
16. Bonney WJ, Spotnitz HM, Liberman L, Silver ES, Ceresnak SR, Hordof AJ et al. Survival of transvenous ICD leads in young patients. Pacing Clin Electrophysiol 2010;33:186-91
17. Von Bergen NH, Atkins DL, Dick M 2nd, Bradley DJ, Etheridge SP, Saarel EV et al. Multicenter study of the effectiveness of implantable cardioverter defibrillators in children and young adults with heart disease. Pediatr Cardiol 2011;32:399-405
18. Alexander ME, Cecchin F, Walsh EP, Triedman JK, Bevilacqua LM, Berul CI. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. J Cardiovasc Electrophysiol 2004;15:72-6
19. Schwartz PJ, Spazzolini C, Priori SG, Crotti L, Vicentini A, Landolina M et al. Who are the long-QT syndrome patients who receive an implantable cardioverterdefibrillator and what happens to them? Data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation 2010;122:1272-82
20. Sy RW, Gollob MH, Klein GJ, Yee R, Skanes AC, Gula LJ et al. Arrhythmia characterization and long-Term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2011;8:864-71
21. Veltmann C, Kuschyk J, Schimpf R, Streitner F, Schoene N, Borggrefe M et al. Prevention of inappropriate ICD shocks in patients with Brugada syndrome. Clin Res Cardiol 2010;99:37-44
22. Sacher F, Probst V, Iesaka Y, Jacon P, Laborderie J, Mizon-Gérard F et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: A multicentre study. Circulation 2006;114:2317-24
23. Koyak Z, de Groot JR, Van Gelder IC, Bouma BJ, van Dessel PF, Budts W et al. Implantable cardioverter defibrillator therapy in adults with congenital heart disease: Who is at risk of shocks? Circ Arrhythm Electrophysiol 2012;5:101-10
24. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol 2011;58:1485-96
25. Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ et al. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart 2009;95:709-14
26. Waldecker B, Brugada P, Zehender M, Stevenson W, Wellens HJ. Dysrhythmias after direct-current cardioversion. Am J Cardiol 1986;57:120-3
27. Weaver WD, Cobb LA, Copass MK, Hallstrom AP. Ventricular defibrillation -A comparative trial using 175-J and 320-J shocks. N Engl J Med 1982;307:1101-6
28. Olde Nordkamp LR, Knops RE, Bardy GH, Blaauw Y, Boersma LV, Bos JS et al. Rationale and design of the PRAETORIAN trial: A Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverterdefibrillator therapy. Am Heart J 2012;163:753-60